Key Challenges and End-to-End ADC CDMO Development Framework
Key Challenges and End-to-End ADC CDMO Development Framework
Antibody–Drug Conjugates (ADCs) manufacturing scale-up is defined as an integrated biopharmaceutical development process combining antibody engineering, linker chemistry, highly potent payload synthesis, and bioconjugation under a unified CDMO platform.
It is essential for enabling scalable, controlled, and GMP-compliant ADC development from discovery to commercialization.
Key Challenges in ADC Manufacturing Scale-up
• Drug-to-Antibody Ratio (DAR) control and optimization
• Conjugation process reproducibility and consistency
• Purification and impurity removal efficiency
• Analytical characterization across development stages
• Seamless scale-up from lab research to GMP manufacturing
• Handling of highly potent payloads under containment systems
• Compliance with strict environmental and safety regulations
ChemExpress CDMO Capabilities in ADC Development
• 10+ years of ADC development and manufacturing experience
• Participation in RC48 ADC development (since 2013), the first self-developed ADC innovative drug in China, supporting payload-linker development and manufacturing
• 100+ ADC IND submissions supported globally
• 6 programs at BLA stage supported
• 1 commercial-stage ADC product supported
• Full lifecycle coverage: discovery → IND → BLA → commercialization
Why Partner with ChemExpress
✔ End-to-end integrated ADC platform covering antibody, payload-linker, DS and DP
✔ Full biologics manufacturing from CHO cell line development to DS/DP production
✔ 150+ payloads in stock, 500+ linkers in stock, 2,000+ linker synthesis experience
✔ Full-spectrum conjugation technologies including lysine, cysteine, site-specific and DAR-controlled approaches
✔ Reduced development cost, timeline, and operational risk via integrated workflow
✔ Controlled supply chain ensuring stable and compliant manufacturing delivery
✔ GMP-compliant quality system aligned with FDA, EMA, and NMPA standards
✔ 700+ ADC experts covering full lifecycle development
End to End Solution for Your ADC Needs
mAbs
• Cell line development (CHO cells)
• DNA to cGMP IND/BLA manufacturing
• Scale: 2×200 L, 500 L, 2,000 L
• Capacity:
• 60 DS batches/year
• ~120,000 L upstream capacity
Payload-Linker
• 150+ payloads in stock
• 500+ linkers in stock
• 2,000+ linker synthesis experience
• 16 FDA DMF-registered ADC payloads/intermediates, includes MMAE, VcMMAE, Exatecan, Eribulin, ect.
• 5 cGMP high-potency API lines
• OEB5 containment
• OEL < 10 ng/m³
• Kilogram-scale production
Conjugation
• Process design & optimization
• Technologies:
• Non-site-specific conjugation (cysteine, lysine)
• Site-specific conjugation (ThioMAb, bridged cysteine, enzyme, N-glycan)
• Process control:
• Process characterization & scale-Up
• Stability & forced degradation
• DAR Control & Analytical Support
• Equipment:
• OEB-5 isolator
• Up to 500 L reactors
Aseptic Fill & Finish
• Liquid and lyophilized formulations
• Lyophilizers: 10 m², 25 m²
• Vial sizes: 2 / 6 / 10 / 20 / 50 mL
• Capacity:
• 5 million vials/year
• ~50 batches/year
Analytical and Quality Control
• ADC characterization:
• Payload distribution
• Conjugation sites
• Aggregates & fragments
• Charge variants
• Release testing:
• Purity and Impurity
• Elisa Assay
• Cell-based assay
• Endotoxin
ADC IND Typical Timeline: ~14 Months from DNA to IND
